TP53 and hepatocellular carcinoma: Collectively, our studies conducted at the clinical, animal, and cellular levels, indicate that NR2E3 loss enhances activation of the Wnt/β‐catenin signaling pathway and p53 inactivation, ultimately promoting HCC development.